Skip to main content
Premium Trial:

Request an Annual Quote

Strand Partners on Indian Breast Cancer Study

NEW YORK (GenomeWeb News) – Strand Life Sciences will work with two institutes on a study in India that aims to identify and validate biomarkers for breast cancer, the Bangalore-based firm said Wednesday.

Strand will partner with the Kidwai Memorial Institute of Oncology and the Indian Institute of Science (IISc) to study more than 300 adult Indian women suffering from breast cancer in an effort to generate molecular signatures that could be used to predict response to various therapies and treatments, metastasis, relapse, and disease-free survival rates.

Strand plans to compare publicly available data from African and Caucasian cohorts with data from this study. It will use the results to develop and identify biological markers that can characterize subtypes and develop diagnostic kits that could be used in making predictions about therapeutic actions.

The company said that breast cancer has overtaken ovarian cancer as the second leading cause of death among women in India's urban centers. Strand also said that recent data suggests that "a startling number of pre-menopausal, young Indian women" are being stricken with the disease.

"It is for the first time in India that such a detailed study of molecular signatures is being undertaken to understand the occurrence and prevalence of breast cancer in the country," Strand Chairman and CEO Vijay Chandru said in a statement. "The objective of this study is to enable groundbreaking research that holds promise to make new, potentially lifesaving discoveries for the Indian population, and we are honored to play a part in unlocking that discovery."

The tumor samples will be provided by the Kidwai Institute and they will be profiled by IISc. Strand will provide in silico analysis of microarray data.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.